Sciensus announced that it has reached an agreement to acquire Vinehealth, a market-leading cancer patient and physician support tool. The addition of Vinehealth further expands Sciensus’s digital platform.
Vinehealth is a cancer support app that empowers cancer patients by enabling them to track, manage and understand their symptoms. The platform creates valuable connectivity with clinical stakeholders, generating actionable insights to optimize clinical decision-making and treatment management.
Sciensus is a pharmaceutical services business established in 1992. The company manages the complex medicine needs of more than 250,000 chronic, rare and cancer patients in the United Kingdom and Europe. In recent years Sciensus has invested heavily to build an integrated portfolio of powerful patient engagement and real-world evidence solutions to enhance patient connectivity and insight.
The founders of Vinehealth said, “This deal marks an important milestone for Vinehealth. Uniting with Sciensus will extend our reach to patients by leveraging their patient network, and relationships with all the leading pharmaceutical companies and healthcare practitioners. Together, we’re poised to enhance the patient experience and generate meaningful patient insights through best-in-class patient support programs and rich longitudinal real-world data to drive advancements in chronic disease patient support.”
Sciensus will accelerate Vinehealth’s expansion into new geographies and therapeutic areas beyond cancer to support patients worldwide. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 28th eHealth acquisition of 2024, and the fourth in the patient engagement specialty. During 2023, there were 273 eHealth and 17 patient engagement transactions announced.
